Unknown Status PHASE2_PHASE3 Interventional 2-arm
NCT01024530
Phase II/III Trial of Hepatocellular Carcinoma Patients Treated by ex Vivo Expanded Autologous Immune Killer Cells as the Adjunct Therapy
Sponsor: Ivy Life Sciences, Co., Ltd
Conditions
Hepatocellular Carcinoma Liver Cancer
Interventions
immune killer cells (IKC)
Updated 2 times since 2017 Last updated: Dec 11, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2_PHASE3 trial investigates Hepatocellular Carcinoma and Liver Cancer and is currently ongoing. Ivy Life Sciences, Co., Ltd leads this study, which shows 2 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
2 versions recorded-
Jun 2018 — Present [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Ivy Life Sciences, Co., Ltd
- Shin Kong Wu Ho-Su Memorial Hospital
Data source: Shin Kong Wu Ho-Su Memorial Hospital
For direct contact, visit the study record on ClinicalTrials.gov .